FIELD: pharmaceuticals.
SUBSTANCE: after administration of sunitinib or its salt are released for a long period of time in concentrations, which are sufficiently high to obtain a therapeutic benefit, but sufficiently low to avoid unacceptable levels of cytotoxicity.
EFFECT: group of inventions discloses compositions providing prolonged release of sunitinib or a pharmaceutically acceptable salt from a polymer matrix, methods of producing and using such compositions, methods of treating intraocular neovascular disease.
33 cl, 9 tbl, 7 dwg
